How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
Akebia Therapeutics is back in focus after analysts trimmed their fair value estimate from US$5.00 to US$4.40, aligning with updated price targets clustered around US$4.00. These moves reflect how research desks are digesting the new US Renal Care dosing protocol and the related US$4.5m to US$5.0m inventory reduction that shaped reported Vafseo revenue in Q4. As you read on, you will see how these shifting targets and the debate around them can help you track the evolving story around this stock. Stay updated as the Fair Value for Akebia Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Akebia Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways BTIG keeps a Buy rating even after trimming its Akebia price target from US$5 to US$4, which signals that the firm still sees upside potential relative to recent trading levels. BTIG frames the Q4 Vafseo impact as tied to a specific U
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswire
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 3/5/26 - Form 4
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- AKBA's page on the SEC website